This seems like an interesting direction for increasing autophagy in the brain…
Background: Status epilepticus (SE) as a severe neurodegenerative disease, greatly negatively affects people’s health, and there is an urgent need for innovative treatments. The valuable neuroprotective effects of glucagon-like peptide-1 (GLP-1) in several neurodegenerative diseases have raised motivation to investigate the dipeptidyl peptidase-4 (DPP-4) inhibitor; alogliptin (ALO), an oral antidiabetic drug as a potential treatment for SE. ALO has shown promising neuroprotective effects in Alzheimer’s and Parkinson’s diseases, but its impact on SE has not yet been studied.
Main methods: ALO (30 mg/kg/day) was administered via gavage for 14 days
Significance: This study suggested that the neuroprotective properties and autophagy-enhancing effects of ALO make it a promising treatment for SE and can potentially be used as a management approach for this condition.
There are several ongoing studies related to neuro protective properties of GLP1-R + GIP drugs (tirzepatide). Two trials on AZ and 1 on PD that I’ve seen registered.
Seems like having a modified version of GLP1 and GIP with a significantly longer half life than what is made in our system has additional benefits
It will be interesting to see what the addition of GCGR to GLP1-R + GIP (retatrutide) does with respect neuro protection.
Dipeptidyl peptidase-4 (DPP-4) inhibitors block the breakdown of GLP-1 and GIP to increase levels of the active hormones. In clinical trials, DPP-4 inhibitors have a modest impact on glycemic control.
